To investigate the biocompatibility, the drug release profile and length of prophylactic efficacy of a biodegradable subcutaneous implant containing antiretroviral drug(s), developed by RTI.
To honor and recognize important work to promote safe injection practices and patient safety and produce educational materials that raise awareness and highlight the work of the One & Only Campaign.
To evaluate the safety, pharmacokinetics and efficacy of macaque-sized CLIP 3D printed intravaginal rings (IVRs) loaded with the potent antiretroviral Islatravir (EFdA) when administered vaginally to pigtailed macaques.
To develop a Global Pediatric Norovirus Laboratory Surveillance Network to monitor norovirus strains and provide data critical for decision-making related to norovirus vaccination.
To support implementation of a set of recommendations and a roadmap developed in the "Strengthening Public Health and Community Based Organization (CBO)" Interface report.
To support two annual two-day conferences for journalists from media outlets reaching rural, frontier and urban populations to provide training on where to access reliable health information.
To screen a subset of human and mouse monoclonal antibodies for their ability to neutralize GI.1; a time ordered panel of GII.4; and GII.3 noroviruses using a novel human intestinal enteroid cell culture system.
To assess the impact of the Pneumococcal conjugate vaccine catch up campaign among internally displaced populations in the northern Sahel region of Burkina Faso. This effort will implement and evaluate the impact of changing the pneumococcal conjugate vaccine schedule.
To assist the Ministry of Public Health (MOPH) in establishing a Field Epidemiology Training Program (FETP) in Qatar focused on building its public health workforce capacity.
To support key laboratory systems strengthening interventions for early disease detection, disease monitoring, and laboratory based disease surveillance for priority diseases of public health importance in Lagos, Nigeria.
To help implement the CDC Foundation programs and activities supporting the Targeted Country Assistance portion of the 2022-2025 Partners’ Engagement Framework.
To build community resilience against weather events by supporting local disaster preparedness programs through community-based organizations in the Midwest, with a focus on rural areas.
To support the introduction of a change in Burkina Faso’s infant pneumococcal vaccine schedule to include a booster dose and to evaluate the impact of the country’s capacity to control pneumococcal disease among children and adults.
To provide project management services to include management of design and performance by CDC of an animal research study involving application of microarray patches (MAPs) containing antiretrovirals for HIV treatment to rhesus macaques.
To evaluate the impact of a pneumococcal conjugate vaccine schedule change in Mozambique on vaccine-type pneumococcal carriage and invasive pneumococcal disease; and serotype 1 colonization among patients with suspected pneumonia and serotype 1 disease among children and adults.
To support a literature review of pneumococcal conjugate vaccines (PCV) dosing schedules and impact assessments to guide discussions about potential changes to current guidance on PCV schedules, an analysis needed to support the WHO Strategic Advisory Group of Experts on Immunization PCV Working Group.
To provide laboratory support for the analysis of immunogenicity and shedding of new oral Poliovirus vaccines in human clinical trials and related issues for polio endgame.
To improve use of antibiotics in outpatient settings, where most prescribing occurs, by providing antibiotic stewardship resources for state health departments and state Medicaid agencies.
To ensure impact and effectiveness of rotavirus vaccines and sustain vaccine use by policy makers, physicians and parents to increase the speed of adoption of vaccine by other countries in Africa and around the world.
To conduct performance evaluations, including operational characteristics of malaria rapid diagnostic tests submitted for WHO for assessment under the WHO Prequalification of In Vitro Diagnostics submitted to WHO for assessment under the Emergency Use Listing.
